Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab plus KPd in Relapsed or Refractory Multiple Myeloma
NCT04287855Phase 2Active, not recruiting
- Sponsor
- CHU de Poitiers
- Start
- Aug 2020
- Primary completion
- Apr 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of isatuximab in multiple myeloma (MM), sponsored by CHU de Poitiers. Primary endpoint: Minimal Residual Disease 10-5 negative rate at 5 years. Started Aug 2020; status: active, not recruiting.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04287855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04287855.